Taiwan Achieves Hepatitis C Elimination Ahead of Schedule
Summary
Taiwan has announced achievement of the World Health Organization's Hepatitis C elimination goal by 2025, well ahead of the global 2030 target. As of October 2025, over 182,000 patients have received direct-acting antiviral (DAA) treatment at a total expenditure of approximately NT$28.7 billion, while over 7.55 million individuals have undergone screening following expanded eligibility. All key indicators have surpassed WHO's Path to Elimination 'Gold Tier' standards, with diagnosis and treatment rates exceeding 90%. The Ministry of Health and Welfare plans to submit the 'Taiwan Hepatitis C Elimination Report' to the WHO Western Pacific Regional Office (WPRO) by the end of 2025.
“Taiwan has met the conditions to achieve the planned Hepatitis C elimination goal by 2025—well ahead of schedule.”
About this source
GovPing monitors MOHW Taiwan News for new consumer protection regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 3 changes logged to date.
What changed
Taiwan's Ministry of Health and Welfare announced that the nation has met and exceeded the World Health Organization's Hepatitis C elimination targets, becoming one of the first countries to achieve 'Gold Tier' status under the WHO's Path to Elimination framework. Key performance indicators show diagnosis and treatment rates surpassing 90%, sterile needle distribution exceeding 150 per person who injects drugs, and 100% blood safety and injection safety records. The achievement was enabled by reimbursement of direct-acting antivirals under National Health Insurance since 2017, progressive expansion of screening eligibility from ages 45-79 to 39-79, and cross-sectoral collaboration across multiple government ministries, local health bureaus, medical institutions, and civic organizations.
For public health authorities and healthcare providers in other jurisdictions, Taiwan's integrated 'Precision Public Health' model — combining expanded DAA reimbursement, population-wide screening, and harm reduction — represents a documented pathway to HCV elimination. The government's stated commitment to sharing prevention and control experiences internationally may yield future policy guidance of interest to hepatitis programs worldwide. No compliance obligations are imposed on private entities by this announcement.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
New Milestone of Hepatitis C Elimination: Taiwan Achieves WHO Goal Ahead of Schedule
- Data Source: Health Promotion Administration, Ministry of Health and Welfare
- Created: 2025-12-17
- Last Updated: 2025-12-17
Taiwan has achieved the World Health Organization’s (WHO) goal of eliminating Hepatitis C by 2025, reaching this milestone ahead of the global timeline. Through cross-sectoral collaboration from central to local levels, the nation has established an integrated strategy covering prevention, screening, and treatment. The results have been outstanding, with all key indicators surpassing the WHO’s Path to Elimination "Gold Tier" standards, including diagnosis and treatment rates exceeding 90%. Taiwan is preparing to submit the "Hepatitis C Elimination Report" to the WHO Regional Office for the Western Pacific (WPRO), demonstrating its commitment to global health standards.
Three-Pronged Approach: Treatment, Screening, and Prevention
In response to the World Health Organization’s (WHO) goal of eliminating viral hepatitis by 2030, the Ministry of Health and Welfare (MOHW) held the International Press Conference on Eliminate Hepatitis C at the Chang Yung-Fa Foundation.
President Lai Ching-Te, and Academician Chen Chien-Jen, Convener of the National Validation Task Force for Hepatitis C Elimination, attended the event. During the conference, officials outlined Taiwan’s achievements in Hepatitis C (HCV) prevention and control, highlighting policy directives such as "Therapy Spearheads Prevention", "Screening Supports Therapy", and "Prevention Secures Outcome " to meet the WHO elimination targets.
Efforts of Cross-Sectoral Collaboration Culminate in Submission of Elimination Report to WHO WPRO
Minister of Health and Welfare Shih Chung-Liang stated that chronic Hepatitis B and C constitute a significant disease burden in Taiwan. To eliminate Hepatitis C, the government has adopted core strategies centered on "Precision Public Health", "Localized Care Delivery" and "Continuum of Care". These strategies aim to provide precise, comprehensive, and effective screening and treatment services.
Since 2003, the government has provided interferon therapy, and in 2017, direct-acting antivirals (DAAs) initiated reimbursement by National Health Insurance (NHI). As of October 2025, over 182,000 patients have received DAA treatment, with a total expenditure of approximately NT$28.7 billion. To boost screening capacity, the government expanded the screening age range to 45–79 years in 2020 and further widened eligibility to those aged 39–79 in 2025. To date, over 7.55 million individuals have undergone screening.
Director-General Shen Ching-Fen of the Health Promotion Administration (HPA) noted that Taiwan’s Programmatic Targets for HCV elimination have surpassed the Gold Tier standards of the WHO’s "Path to Elimination" (PTE). Both diagnosis and treatment rates now exceed 90%. Regarding prevention and harm reduction measures, the average number of sterile needles and syringes distributed per person who injects drugs (PWID) exceeds 150, while blood safety and injection safety have maintained a 100% record.
Having achieved these staged elimination goals, the Administration aims to further reduce the incidence of Hepatitis C and mortality rates attributable to Hepatitis B and C. Future efforts will focus on strengthening screening, health education campaigns to raise public awareness, and improving treatment accessibility. The public is strongly encouraged to undergo screening and seek early follow-up treatment to consolidate the nation's success in eliminating Hepatitis C.
Through cross-sectoral collaboration involving the MOHW’s Department of Medical Affairs, Department of Mental Health, National Health Insurance Administration (NHIA), Taiwan Centers for Disease Control, and Taiwan Food and Drug Administration, alongside the Ministry of Justice’s Agency of Corrections, local health bureaus, medical institutions, and civic organizations, Taiwan has met the conditions to achieve the planned Hepatitis C elimination goal by 2025—well ahead of schedule.
The government plans to submit the "Taiwan Hepatitis C Elimination Report" to the WHO Western Pacific Regional Office (WPRO) by the end of this year. Moving forward, Taiwan remains committed to implementing relevant control measures and sharing its successful prevention and control experiences with the international community
- ;)
收合
Related changes
Get daily alerts for MOHW Taiwan News
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from MOHW Taiwan.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when MOHW Taiwan News publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.